CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response ; volume:10 ; number:1 ; day:26 ; month:10 ; year:2024 ; pages:1-16 ; date:12.2024
Cell death discovery ; 10, Heft 1 (26.10.2024), 1-16, 12.2024

Creator: Hong, Ting
Hogger, Anna C.
Wang, Dongbiao
Pan, Qi
Gansel, Julie
Engleitner, Thomas
Öllinger, Rupert
Gschwend, Jürgen E.
Rad, Roland
Nawroth, Roman

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41420-024-02218-6

URN: urn:nbn:de:101:1-2501162102514.794333465330

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Hong, Ting
Hogger, Anna C.
Wang, Dongbiao
Pan, Qi
Gansel, Julie
Engleitner, Thomas
Öllinger, Rupert
Gschwend, Jürgen E.
Rad, Roland
Nawroth, Roman
SpringerLink (Online service)

Other Objects (12)

CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition

CDK4, pRB and E2F1: connected to insulin

Regulation of CDK4

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Parametric multistep methods

Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

A prefrontal motor circuit initiates persistent movement

Archivale

Rampendaler Bauerschaft (RB 3, RB 4, RB 6, RB 15, RB 19, RB 36c, RB 40, RB 47, RB 50, RB 55, RB 60, RB 61, RB 62, RB 63, RB 64, RB 65, RB 81, RB 84, RB 85, RB 86, RB 87, RB 88RB 96, RB 100, RB 100, RB 101, RB 103, RB 105, RB 109, RB 113, RB 114, RB 115, RB 116, RB 117, RB 118

Abschnitt

Translocation

Robustness of performance and stability for multistep and updated multistep MPC schemes

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition

CDK4, pRB and E2F1: connected to insulin

Regulation of CDK4

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Parametric multistep methods

Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

A prefrontal motor circuit initiates persistent movement

Archivale

Rampendaler Bauerschaft (RB 3, RB 4, RB 6, RB 15, RB 19, RB 36c, RB 40, RB 47, RB 50, RB 55, RB 60, RB 61, RB 62, RB 63, RB 64, RB 65, RB 81, RB 84, RB 85, RB 86, RB 87, RB 88RB 96, RB 100, RB 100, RB 101, RB 103, RB 105, RB 109, RB 113, RB 114, RB 115, RB 116, RB 117, RB 118

Abschnitt

Translocation

Robustness of performance and stability for multistep and updated multistep MPC schemes

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition

CDK4, pRB and E2F1: connected to insulin

Regulation of CDK4

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Parametric multistep methods

Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

A prefrontal motor circuit initiates persistent movement

Archivale

Rampendaler Bauerschaft (RB 3, RB 4, RB 6, RB 15, RB 19, RB 36c, RB 40, RB 47, RB 50, RB 55, RB 60, RB 61, RB 62, RB 63, RB 64, RB 65, RB 81, RB 84, RB 85, RB 86, RB 87, RB 88RB 96, RB 100, RB 100, RB 101, RB 103, RB 105, RB 109, RB 113, RB 114, RB 115, RB 116, RB 117, RB 118

Abschnitt

Translocation

Robustness of performance and stability for multistep and updated multistep MPC schemes

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition

CDK4, pRB and E2F1: connected to insulin

Regulation of CDK4

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Parametric multistep methods

Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

A prefrontal motor circuit initiates persistent movement

Rampendaler Bauerschaft (RB 3, RB 4, RB 6, RB 15, RB 19, RB 36c, RB 40, RB 47, RB 50, RB 55, RB 60, RB 61, RB 62, RB 63, RB 64, RB 65, RB 81, RB 84, RB 85, RB 86, RB 87, RB 88RB 96, RB 100, RB 100, RB 101, RB 103, RB 105, RB 109, RB 113, RB 114, RB 115, RB 116, RB 117, RB 118

Translocation

Robustness of performance and stability for multistep and updated multistep MPC schemes

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition

CDK4, pRB and E2F1: connected to insulin

Regulation of CDK4

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Parametric multistep methods

Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

A prefrontal motor circuit initiates persistent movement

Rampendaler Bauerschaft (RB 3, RB 4, RB 6, RB 15, RB 19, RB 36c, RB 40, RB 47, RB 50, RB 55, RB 60, RB 61, RB 62, RB 63, RB 64, RB 65, RB 81, RB 84, RB 85, RB 86, RB 87, RB 88RB 96, RB 100, RB 100, RB 101, RB 103, RB 105, RB 109, RB 113, RB 114, RB 115, RB 116, RB 117, RB 118

Translocation

Robustness of performance and stability for multistep and updated multistep MPC schemes

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition

CDK4, pRB and E2F1: connected to insulin

Regulation of CDK4

PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Parametric multistep methods

Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity

LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway

A prefrontal motor circuit initiates persistent movement

Rampendaler Bauerschaft (RB 3, RB 4, RB 6, RB 15, RB 19, RB 36c, RB 40, RB 47, RB 50, RB 55, RB 60, RB 61, RB 62, RB 63, RB 64, RB 65, RB 81, RB 84, RB 85, RB 86, RB 87, RB 88RB 96, RB 100, RB 100, RB 101, RB 103, RB 105, RB 109, RB 113, RB 114, RB 115, RB 116, RB 117, RB 118

Translocation

Robustness of performance and stability for multistep and updated multistep MPC schemes

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Related objects

Reset password